| 2024-05-09 |
详情>>
业绩披露：
2024年一季报每股收益-2.16美元,归母净利润-883.4万美元,同比去年增长11.78%
|
| 2024-04-26 |
股东大会：
将于2024-06-13召开股东大会
会议内容 ▼▲
- 1.To elect two directors to serve as Class III directors for a three-year term expiring at the 2027 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified;
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;
3.To approve an amendment to our Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 40,000,000 to 80,000,000;
4.To transact such other business as may properly come before the Annual Meeting or any continuation, postponement or adjournment of the Annual Meeting.
|
| 2024-04-26 |
详情>>
股本变动：
变动后总股本470.44万股
|
| 2024-04-04 |
复牌提示：
2024-04-04 10:31:48 停牌，复牌日期 2024-04-04 10:36:48
|
| 2024-03-26 |
详情>>
业绩披露：
2023年年报每股收益-16.37美元,归母净利润-3581.1万美元,同比去年增长-58%
|
| 2024-01-12 |
详情>>
拆分方案：
每25.0000合并分成1.0000股
|
| 2023-11-13 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.53美元,归母净利润-2668.1万美元,同比去年增长-99.04%
|
| 2023-08-08 |
详情>>
业绩披露：
2023年中报每股收益-0.41美元,归母净利润-1837.8万美元,同比去年增长-377.85%
|
| 2023-05-12 |
股东大会：
将于2023-06-22召开股东大会
会议内容 ▼▲
- 1.To elect three directors to serve as Class II directors for a three-year term expiring at the 2026 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified;
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023;
3.To approve an amendment to our Amended and Restated Certificate of Incorporation to reflect new Delaware law provisions to permit exculpation of certain officers;
4.To grant our board of directors authority to effect a reverse stock split of our outstanding common stock by amending our Amended and Restated Certificate of Incorporation within one year and within a range of not less than one-for-five and not more than one-for-thirty, and a proportionate reduction in the number of authorized shares of our common stock;
5.To transact such other business as may properly come before the Annual Meeting or any continuation, postponement or adjournment of the Annual Meeting.
|
| 2023-05-09 |
详情>>
业绩披露：
2023年一季报每股收益-0.24美元,归母净利润-1001.4万美元,同比去年增长-426.3%
|
| 2023-03-08 |
详情>>
业绩披露：
2022年年报每股收益-0.55美元,归母净利润-2266.5万美元,同比去年增长-243.47%
|
| 2022-11-07 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-0.33美元,归母净利润-1340.5万美元,同比去年增长-312.33%
|
| 2022-08-09 |
详情>>
业绩披露：
2022年中报每股收益-0.09美元,归母净利润-384.6万美元,同比去年增长68.29%
|
| 2022-05-10 |
详情>>
业绩披露：
2022年一季报每股收益0.08美元,归母净利润306.90万美元,同比去年增长146.63%
|
| 2022-04-20 |
股东大会：
将于2022-06-09召开股东大会
会议内容 ▼▲
- 1.To elect two directors to serve as Class I directors for a three-year term expiring at the 2025 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified;
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
3.To transact such other business as may properly come before the Annual Meeting or any continuation, postponement or adjournment of the Annual Meeting.
|
| 2022-03-16 |
详情>>
业绩披露：
2021年年报每股收益1.05美元,归母净利润1579.80万美元,同比去年增长9416.87%
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-08-25 |
详情>>
内部人交易：
WORLAND STEPHEN T等共交易4笔
|
| 2021-08-10 |
股东大会：
将于2021-08-24召开股东大会
会议内容 ▼▲
- 1.To consider and vote upon a proposal to approve the transactions contemplated under the Agreement and Plan of Merger, dated as of May 26, 2021 (the “Merger Agreement”), by and among LWAC, Locust Walk Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of LWAC (“Merger Sub”), and eFFECTOR Therapeutics, Inc., a Delaware corporation (“eFFECTOR”) (the “Business Combination”), a copy of which is attached to this proxy statement/prospectus as Annex A, pursuant to which Merger Sub will merge with and into eFFECTOR (the “Merger”) with eFFECTOR surviving the Merger as a wholly owned subsidiary of LWAC. This proposal is referred to as the “Transaction Proposal” or “Proposal 1.”
2.To consider and vote upon a proposal to approve the Amended and Restated Certificate of Incorporation of LWAC, a copy of which is attached to this proxy statement/prospectus as Annex B (the “Proposed Charter”), to, among other things, change LWAC’s name to “eFFECTOR Therapeutics, Inc.,” amend certain provisions related to authorized capital stock, the required vote to amend the charter and bylaws, and director removal, and to divide the board of directors into three classes, with one class of directors being elected in each year and each class (except for those directors appointed to our first annual meeting of stockholders) serving a three-year term, in each case, to be effective upon the consummation of the Business Combination. This proposal is referred to as the “Amendment Proposal” or “Proposal 2.”
3.To consider and vote upon a proposal to approve the eFFECTOR Therapeutics, Inc. 2021 Incentive Award Plan (the “Incentive Plan”), a copy of which is attached to this proxy statement/prospectus as Annex D, to be effective upon the consummation of the Business Combination. This proposal is referred to as the “Incentive Plan Proposal” or “Proposal 3.”
4.To consider and vote upon a proposal to approve the eFFECTOR Therapeutics, Inc. 2021 Employee Stock Purchase Plan (the “ESPP”), a copy of which is attached to this proxy statement/prospectus as Annex E, to be effective upon the consummation of the Business Combination. This proposal is referred to as the “ESPP Proposal” or “Proposal 4.”
5.To consider and vote upon a proposal to approve: (i) for purposes of complying with Nasdaq Listing Rule 5635 (a) and (b), the issuance of more than 20% of the issued and outstanding shares of our common stock and the resulting change in control in connection with the Merger, and (ii) for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of more than 20% of our common stock in a private placement to certain accredited investors upon the consummation of the Business Combination. This proposal is referred to as the “Nasdaq Proposal” or “Proposal 5.”
6.To consider and vote upon a proposal to approve the adjournment of the Meeting by the chairman thereof to a later date, if necessary, under certain circumstances, including for the purpose of soliciting additional proxies in favor of the foregoing Proposals, in the event LWAC does not receive the requisite stockholder vote to approve the Proposals. This proposal is called the “Adjournment Proposal” or “Proposal 6.”
|